Search research articles
Contact Us
Filters
Showing results (141-150 of 152) with videos related to
Page
of 16
Sort By:
Proceedings of the National Academy of Sciences of the United States of America
|
April 15, 2026
Self-adjuvanting α-helical polypeptide simultaneously delivers neoantigen mRNAs and activates dendritic cells to eradicate tumors
Joonsu Han, Jiadiao Zhou, Abhisek Dwivedy, et al.
Zootaxa
|
July 11, 2016
Additions to Philippine Slender Skinks of the Brachymeles bonitae Complex (Reptilia: Squamata: Scincidae) III: a new species from Tablas Island
Drew R Davis, Aaron D Geheber, Jessa L Watters, et al.
Blood Vessels, Thrombosis & Hemostasis
|
January 8, 2026
Automated natural language processing to identify venous thromboembolism from diagnostic imaging reports
Naveen Subramanian, Hector Garcia Pleitez, Daniel Nguyen, et al.
Pathogens (Basel, Switzerland)
|
May 27, 2026
Viral Risks at the Human-Bat Interface: Household Bat Guano Farming in Rural Cambodia
Theara Teng, Sarin Neang, Bruno M Ghersi, et al.
The Lancet. Haematology
|
September 20, 2024
Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial
Nicholas J Short, Daniel Nguyen, Elias Jabbour, et al.
Cancer
|
March 9, 2023
Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation
Daniel Nguyen, Hagop M Kantarjian, Nicholas J Short, et al.
American Journal of Hematology
|
September 2, 2022
Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD-negative remission
Nicholas J Short, Walid Macaron, Tapan Kadia, et al.
Journal of Hematology & Oncology
|
June 27, 2026
Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II study
Nicholas J Short, Alex Bataller, Courtney D DiNardo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 22, 2026
Investigational clinical trial agents versus conventional second salvage therapies in patients with relapsed/refractory acute myeloid leukemia
Daniel Nguyen, Hagop M Kantarjian, Aram Bidikian, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
June 29, 2023
Universal evaluation of MLC models in treatment planning systems based on a common set of dynamic tests
Jordi Saez, Raquel Bar-Deroma, Evelien Bogaert, et al.
Page
of 16
Search research articles
Search
Showing results (141-150 of 152) with videos related to
Sort By:
Page
of 16
Proceedings of the National Academy of Sciences of the United States of America
|
April 15, 2026
Self-adjuvanting α-helical polypeptide simultaneously delivers neoantigen mRNAs and activates dendritic cells to eradicate tumors
Joonsu Han, Jiadiao Zhou, Abhisek Dwivedy, et al.
Zootaxa
|
July 11, 2016
Additions to Philippine Slender Skinks of the Brachymeles bonitae Complex (Reptilia: Squamata: Scincidae) III: a new species from Tablas Island
Drew R Davis, Aaron D Geheber, Jessa L Watters, et al.
Blood Vessels, Thrombosis & Hemostasis
|
January 8, 2026
Automated natural language processing to identify venous thromboembolism from diagnostic imaging reports
Naveen Subramanian, Hector Garcia Pleitez, Daniel Nguyen, et al.
Pathogens (Basel, Switzerland)
|
May 27, 2026
Viral Risks at the Human-Bat Interface: Household Bat Guano Farming in Rural Cambodia
Theara Teng, Sarin Neang, Bruno M Ghersi, et al.
The Lancet. Haematology
|
September 20, 2024
Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial
Nicholas J Short, Daniel Nguyen, Elias Jabbour, et al.
Cancer
|
March 9, 2023
Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation
Daniel Nguyen, Hagop M Kantarjian, Nicholas J Short, et al.
American Journal of Hematology
|
September 2, 2022
Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD-negative remission
Nicholas J Short, Walid Macaron, Tapan Kadia, et al.
Journal of Hematology & Oncology
|
June 27, 2026
Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II study
Nicholas J Short, Alex Bataller, Courtney D DiNardo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 22, 2026
Investigational clinical trial agents versus conventional second salvage therapies in patients with relapsed/refractory acute myeloid leukemia
Daniel Nguyen, Hagop M Kantarjian, Aram Bidikian, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
June 29, 2023
Universal evaluation of MLC models in treatment planning systems based on a common set of dynamic tests
Jordi Saez, Raquel Bar-Deroma, Evelien Bogaert, et al.
Page
of 16